UroGen Pharma Ltd
(NAS:URGN)
$
11.21
0.51 (4.77%)
Market Cap: 473.06 Mil
Enterprise Value: 345.40 Mil
PE Ratio: 0
PB Ratio: 18.53
GF Score: 75/100 Urogen Pharma Ltd at Cowen Healthcare Conference (Virtual) Transcript
Mar 02, 2021 / 02:10PM GMT
Release Date Price:
$19.73
(-3.57%)
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Welcome, everybody, to the second day of our conference. I'm Boris Peaker. I'm one of the biotech analysts at Cowen. It's my pleasure to host a fireside chat with UroGen, and with us is Liz Barrett from UroGen. Welcome, Liz.
Elizabeth A. Barrett
UroGen Pharma Ltd. - President, CEO & Director
Hello. Thank you. Hi, everyone. Glad to be here.
Questions & Answers
Boris Peaker
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
So let's just jump right in. You recently had a Jelmyto approved. Can you comment what you're seeing from the commercial launch of the drug and how we should be thinking about it over the next maybe a year or 2 or even longer term.
Elizabeth A. Barrett
UroGen Pharma Ltd. - President, CEO & Director
Sure. Absolutely. I think everybody knows we launched June 1, so right in the middle of a pandemic. I always think about
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot